Source: https://www.fr.com/fish-litigation/court-confirms-unique-pleading-requirements-in-hatch-waxman-actions/
Timestamp: 2019-04-25 14:50:24+00:00

Document:
In a March 31, 2019 opinion in Belcher Pharmaceuticals LLC v. International Mediation Systems, Limited, Judge Stark of the Delaware District Court held that complaints in Hatch-Waxman actions can satisfy the requirements imposed by Ashcroft v. Iqbal, 556 U.S. 662 (2009), and Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007), “as applied to the unique context of a Hatch-Waxman claim for patent infringement.” C.A. No. 19-960-LPS-CJB, D.I. 30 at 9 (D. Del.) (“Mem. Op.”).
There, the defendant filed an application under 21 U.S.C. § 355(b)(2), often called a “paper NDA,” and sent a Paragraph IV Notice to plaintiff. The parties subsequently negotiated an offer of confidential access, and the defendant provided its entire 4,000 page NDA to plaintiff about three weeks prior to the 45-day deadline for filing suit. In its complaint, plaintiff alleged that the defendant infringed claims 6 and 7 of the asserted patent under 35 U.S.C. §§ 271(a)-(c) and 271(e)(2) by filing its 505(b)(2) application. See C.A. No. 19-960-LPS-CJB, D.I. 1 at 6.
In essence, Defendant’s position is that while the Hatch Waxman Act creates subject matter jurisdiction over the ‘artificial act of infringement’ of filing a paper NDA ( or ANDA), actual infringement still must be pled with particularity to survive a Rule 12(b)(6) motion.
In the Court’s view, both the language and the purpose of the Hatch-Waxman Act establish that a plaintiff in receipt of a paragraph IV certification providing notice of the filing of an ANDA (or, as here, a paper NDA) relating to one of the plaintiff’s Orange Book-listed patents may state a claim for infringement by alleging its interest in the patent, its receipt of the paragraph IV certification, the filing of the ANDA or NDA, and its contention that the defendant’s proposed product will infringe.
Id. at 6-7 (citing 271(e)(2)(A)).
Lastly, the court noted that, because the defendant had applied for FDA approval for a drug listed in the Orange Book, it “already knows at least some of the reason” for plaintiff’s suit. Id. at 8-9.
Although the underlying facts, such as the pre-complaint information exchange and the assertion of specific claims may be atypical, this decision appears to confirm the unique pleading standards for Hatch-Waxman complaints based on artificial acts of infringements under § 271(e)(2).
 Over defendant’s objection, the court concluded the same pleading standard applies to both ANDA actions under § 505(j) and paper NDA actions under § 505(b)(2). Id. at 6 n.3.
View our upcoming webinar “Q1 Update on Hatch-Waxman Litigation” on Thursday, April 25th to keep current on Hatch-Waxman topics, including litigation strategies.

References: v. 
 v. 
 v. 
 § 355
 § 271
 § 505
 § 505